Agency also authorized a second booster for Americans 12 and older who are immune-compromised
2019 to 2020 Saw Risk-Linked Deaths From Heart Disease, Stroke Up
Highest risk-associated increases were seen in non-Hispanic Black people followed by Hispanics, non-Hispanic Asian or Pacific Islanders
No Adverse Outcomes Seen With SARS-CoV-2 Vaccination in Pregnancy
No significantly increased risk reported for preterm birth, stillbirth, SGA, low Apgar score, or neonatal care admission
Memory Deficits Seen in Individuals With ‘Long COVID’
Deficits increased with severity of ongoing self-reported symptoms; severity of initial illness did not influence later cognitive performance
Immune Response to SARS-CoV-2 Infection Persists in Children
Ninety-six percent of those with evidence of nucleocapsid antibodies at baseline still had antibodies more than six months later
$24 Million in Grants Will Help End the HIV Epidemic
Gilead Sciences, Inc. today announced $24 million in new grants that will help reduce health disparities, improve access to quality healthcare, advance medical education and support local communities most impacted by the HIV epidemic and COVID-19 pandemic.
Gilead confirmed the Zeroing In: Ending the HIV Epidemic program will support 116 organizations in 41 countries.
The funding recipients will focus on advancing at least one of three focus areas: Comprehensive HIV Innovation, Digital Health Innovation, and Community Outreach and Education.
Biden Administration to Offer Second COVID-19 Boosters to Those 50+
While a second booster for older adults will be offered, federal health officials will not go so far as to recommend it
Many Local Health Departments Report Harassment During Pandemic
Public health officials reported experiencing structural and political undermining of their professional duties
RSV Vaccine Candidates Approach the Starting Gate
After decades of false starts, new research indicates four Respiratory Syncytial Virus (RSV) vaccine candidates are nearing the completion of late-stage trials.
According to the U.S. CDC, RSV vaccines could drastically reduce hospital and intensive-care admissions for young children and seniors.
Unfortunately, an earlier version created sickness in children.
RSV infections are usually most severe in infants under two months old, who encounter the virus for the first time.
Tetanus Immunity Leveraged Against Pancreatic Cancer
Pancreatic cancer is notoriously difficult to cure or even treat. Now, a new strategy devised by scientists at New York-based Albert Einstein College of Medicine has succeeded in making pancreatic tumors visible to the immune systems of mice and vulnerable to immune attack, reducing cancer metastases by 87%.
Published by SCIENCE TRANSLATIONAL MEDICINE on March 23, 2022, these researchers wrote, ‘immunotherapy has been of little use at treating highly aggressive pancreatic ductal adenocarcinoma (PDAC) due to its immunosuppressive tumor microenvironment.’